Federal Register / Vol. 87, No. 136 / Monday, July 18, 2022 / Notices 42727 

Dated: July 12, 2022. 

Sarah L. Stewart, 

Deputy General Counsel, Federal Mine Safety 

and Health Review Commission. 

[FR Doc. 2022–15277 Filed 7–15–22; 8:45 am] 

BILLING CODE 6735–01–P 

FEDERAL RESERVE SYSTEM 

Change in Bank Control Notices; 

Acquisitions of Shares of a Bank or 

Bank Holding Company 

The notificants listed below have 

applied under the Change in Bank 

Control Act (Act) (12 U.S.C. 1817(j)) and 

§ 225.41 of the Board’s Regulation Y (12 

CFR 225.41) to acquire shares of a bank 

or bank holding company. The factors 

that are considered in acting on the 

applications are set forth in paragraph 7 

of the Act (12 U.S.C. 1817(j)(7)). 

The public portions of the 

applications listed below, as well as 

other related filings required by the 

Board, if any, are available for 

immediate inspection at the Federal 

Reserve Bank(s) indicated below and at 

the offices of the Board of Governors. 

This information may also be obtained 

on an expedited basis, upon request, by 

contacting the appropriate Federal 

Reserve Bank and from the Board’s 

Freedom of Information Office at 

https://www.federalreserve.gov/foia/ 

request.htm. Interested persons may 

express their views in writing on the 

standards enumerated in paragraph 7 of 

the Act. 

Comments regarding each of these 

applications must be received at the 

Reserve Bank indicated or the offices of 

the Board of Governors, Ann E. 

Misback, Secretary of the Board, 20th 

Street and Constitution Avenue NW, 

Washington, DC 20551–0001, not later 

than August 2, 2022. 

A. Federal Reserve Bank of Chicago 

(Colette A. Fried, Assistant Vice 

President) 230 South LaSalle Street, 

Chicago, Illinois 60690–1414: 

1. The Bell Family Voting Trust 

(‘‘Trust’’), Wisconsin Rapids, Wisconsin 

and Steven C. Bell and Paula J. Bell, 

both of Wisconsin Rapids, Wisconsin, 

Elizabeth Bell Killian, Spokane, 

Washington, Rebecca L. Kettleson, 

Wausau, Wisconsin and Margaret S. 

Bell, Chicago, Illinois, all co-trustees of 

the Trust; to become members of the 

Bell Family Control Group, a group 

acting in concert, to acquire voting 

shares of WoodTrust Financial 

Corporation, and thereby indirectly 

acquire voting shares of WoodTrust 

Bank, both of Wisconsin Rapids, 

Wisconsin. 

Board of Governors of the Federal Reserve 

System. 

Michele Taylor Fennell, 

Deputy Associate Secretary of the Board. 

[FR Doc. 2022–15274 Filed 7–15–22; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

[OMB No. 0970–0036] 

Submission for OMB Review; ORR–6 

Performance Report 

AGENCY: Office of Refugee Resettlement, 

Administration for Children and 

Families, HHS. 

ACTION: Request for Public Comment. 

SUMMARY: The Administration for 

Children and Families (ACF), Office of 

Refugee Resettlement (ORR) is 

requesting a renewal of the ORR–6 

Performance Report (OMB #0970–0036, 

expiration 03/31/2023). ORR published 

a notice in the Federal Register on 8/12/ 

2021 requesting comments within 60- 

days on revisions to the ORR–6. 

DATES: Comments due within 30 days of 

publication. OMB must make a decision 

about the collection of information 

between 30 and 60 days after 

publication of this document in the 

Federal Register. Therefore, a comment 

is best assured of having its full effect 

if OMB receives it within 30 days of 

publication. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. You can also obtain 

copies of the proposed collection of 

information by emailing infocollection@

acf.hhs.gov. Identify all emailed 

requests by the title of the information 

collection. 

SUPPLEMENTARY INFORMATION:

Description: ACF/ORR requests 

information from the ORR–6 

Performance Report to determine 

effectiveness of state Cash and Medical 

Assistance (CMA) and Refugee Support 

Services programs. ORR uses state-bystate CMA utilization rates, derived 

from the ORR–6 Performance Report, to 

formulate program initiatives, priorities, 

standards, budget requests, and 

assistance policies. Federal regulations 

require state Refugee Resettlement, 

Replacement Designee agencies, and 

local governments submit statistical or 

programmatic information that the ORR 

Director determines to be required to 

fulfill their responsibility under the 

Immigration and Nationality Act (INA). 

The currently approved ORR–6 has been 

updated to add new data elements to 

better understand the meaning of 

existing data collection, and update the 

instructions and reformat some of the 

forms to provide clearer definitions and 

better distinguish the participation and 

performance results of different support 

services programs. In addition, some 

revisions are related to Afghanistan 

Supplemental Appropriations Act 2022, 

Additional Afghanistan Supplemental 

Appropriations Act 2022, and 

Additional Ukraine Supplemental 

Appropriations Act 2022 

Respondents: State governments and 

Replacement Designees. 

ANNUAL BURDEN ESTIMATES

Instrument Total number 

of respondents 

Total No. of 

responses per 

respondent 

Average burden hours per 

response 

Total burden 

hours 

Annual burden 

hours 

ORR–6 Performance Report ............................................... 64 6 15 5,760 1,920 


khammond on DSKJM1Z7X2PROD with NOTICES
42728 Federal Register / Vol. 87, No. 136 / Monday, July 18, 2022 / Notices 

Estimated Total Annual Burden 

Hours: 1,920. 

Authority: 8 U.S.C 1522 of the 

Immigration and Nationality Act (the 

Act) (Title IV, Sec. 412 of the Act), and 

45 CFR 400.28(b). 

Mary B. Jones, 

ACF/OPRE Certifying Officer. 

[FR Doc. 2022–15227 Filed 7–15–22; 8:45 am] 

BILLING CODE 4184–45–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–1999–D–2955 (formerly 

1999D–4071)] 

International Cooperation on 

Harmonisation of Technical 

Requirements for Registration of 

Veterinary Medicinal Products; 

Impurities: Residual Solvents in New 

Veterinary Medicinal Products, Active 

Substances and Excipients (Revision 

2); Draft Guidance for Industry; 

Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of availability. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing the availability of a draft 

guidance for industry (GFI) #100 (VICH 

GL 18(R2)) entitled ‘‘Impurities: 

Residual Solvents in New Veterinary 

Medicinal Products, Active Substances 

and Excipients (Revision 2).’’ This draft 

guidance has been developed for 

veterinary use by the International 

Cooperation on Harmonisation of 

Technical Requirements for Registration 

of Veterinary Medicinal Products 

(VICH). The objective of this draft 

guidance is to recommend acceptable 

amounts for residual solvents in 

pharmaceuticals for the safety of the 

target animal as well as for the safety of 

residues in products derived from 

treated food-producing animals. This 

revision updates the listings and 

classification of solvents. 

DATES: Submit either electronic or 

written comments on the draft guidance 

by September 16, 2022 to ensure that 

the Agency considers your comment on 

this draft guidance before it begins work 

on the final version of the guidance. 

ADDRESSES: You may submit comments 

on any guidance at any time as follows: 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 

identifies you in the body of your 

comments, that information will be 

posted on https://www.regulations.gov. 

• If you want to submit a comment 

with confidential information that you 

do not wish to be made available to the 

public, submit the comment as a 

written/paper submission and in the 

manner detailed (see ‘‘Written/Paper 

Submissions’’ and ‘‘Instructions’’). 

Written/Paper Submissions 

Submit written/paper submissions as 

follows: 

• Mail/Hand Delivery/Courier (for 

written/paper submissions): Dockets 

Management Staff (HFA–305), Food and 

Drug Administration, 5630 Fishers 

Lane, Rm. 1061, Rockville, MD 20852. 

• For written/paper comments 

submitted to the Dockets Management 

Staff, FDA will post your comment, as 

well as any attachments, except for 

information submitted, marked and 

identified, as confidential, if submitted 

as detailed in ‘‘Instructions.’’ 

Instructions: All submissions received 

must include the Docket No. FDA– 

1999–D–2955 (formerly 1999D–4071) 

for ‘‘Impurities: Residual Solvents in 

New Veterinary Medicinal Products, 

Active Substances and Excipients 

(Revision 2).’’ Received comments will 

be placed in the docket and, except for 

those submitted as ‘‘Confidential 

Submissions,’’ publicly viewable at 

https://www.regulations.gov or at the 

Dockets Management Staff between 9 

a.m. and 4 p.m., Monday through 

Friday, 240–402–7500. 

• Confidential Submissions—To 

submit a comment with confidential 

information that you do not wish to be 

made publicly available, submit your 

comments only as a written/paper 

submission. You should submit two 

copies total. One copy will include the 

information you claim to be confidential 

with a heading or cover note that states 

‘‘THIS DOCUMENT CONTAINS 

CONFIDENTIAL INFORMATION.’’ The 

Agency will review this copy, including 

the claimed confidential information, in 

its consideration of comments. The 

second copy, which will have the 

claimed confidential information 

redacted/blacked out, will be available 

for public viewing and posted on 

https://www.regulations.gov. Submit 

both copies to the Dockets Management 

Staff. If you do not wish your name and 

contact information to be made publicly 

available, you can provide this 

information on the cover sheet and not 

in the body of your comments and you 

must identify this information as 

‘‘confidential.’’ Any information marked 

as ‘‘confidential’’ will not be disclosed 

except in accordance with 21 CFR 10.20 

and other applicable disclosure law. For 

more information about FDA’s posting 

of comments to public dockets, see 80 

FR 56469, September 18, 2015, or access 

the information at: https://

www.govinfo.gov/content/pkg/FR-2015- 

09-18/pdf/2015-23389.pdf. 

Docket: For access to the docket to 

read background documents or the 

electronic and written/paper comments 

received, go to https://

www.regulations.gov and insert the 

docket number, found in brackets in the 

heading of this document, into the 

‘‘Search’’ box and follow the prompts 

and/or go to the Dockets Management 

Staff, 5630 Fishers Lane, Rm. 1061, 

Rockville, MD 20852, 240–402–7500. 

You may submit comments on any 

guidance at any time (see 21 CFR 

10.115(g)(5)). 

Submit written requests for single 

copies of this draft guidance to the 

Policy and Regulations Staff (HFV–6), 

Center for Veterinary Medicine, 7500 

Standish Pl., Rockville, MD 20855. Send 

one self-addressed adhesive label to 

assist that office in processing your 

request or include a fax number to 

which the draft guidance may be sent. 

See the SUPPLEMENTARY INFORMATION

section for information on electronic 

access to the draft guidance. 

FOR FURTHER INFORMATION CONTACT: Mai 

Huynh, Center for Veterinary Medicine 

(HFV–140), Food and Drug 

Administration, 7500 Standish Pl., 

Rockville, MD 20855, 240–402–0669, 

mai.huynh@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: 

I. Background 

FDA is announcing the availability of 

a draft GFI #100 (VICH GL18(R2)) 

entitled ‘‘Impurities: Residual Solvents 

in New Veterinary Medicinal Products, 

Active Substances and Excipients 

(Revision 2).’’ Residual solvents in 

pharmaceuticals are defined in the 

guidance as organic volatile chemicals 

that are used or produced in the 

manufacture of active substances or 


khammond on DSKJM1Z7X2PROD with NOTICES